Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2014

View Archived Issues

Eli Lilly and Immunocore to discover and develop novel cancer therapies

TTP-054 demonstrates the ability to lower HbA1c in patients with type 2 diabetes

Chase Pharmaceuticals to begin phase II study of CPC-201

Researchers present novel ASOs as potential therapies for tauopathies

Virobay completes series B financing round

Enrollment completed in study of protein-based biomarker blood test for breast cancer

Novel agents for tuberculosis patented by Janssen R&D Ireland

Galapagos designs new GPR84 agonists

Cellerant Therapeutics divulges new anti-IL1RAP MAbs

AVEO Pharmaceuticals presents new anti-GDF-15 MAbs

Researchers at Rockefeller University patent new modified anti-CD4 MAbs

Significant benefits seen with DA-1229 in diabetes trial

New anti-Notch 3 antibodies selected by AVEO Pharmaceuticals

French group patents new spiroisoxazoline derivatives

Phase III trial of biosimilar of etanercept begins in chronic plaque psoriasis

Capricor Therapeutics reports results from phase I portion of the ALLSTAR trial

Isis Pharmaceuticals begins phase II study of ISIS-APO(a)Rx in patients with high Lp(a)

ImQuest Pharmaceuticals receives FDA approval to initiate trials of IQP-0528 gel

Resolve Therapeutics begins phase II study of RSLV-132 in SLE

OncoMed Pharmaceuticals begins phase II ALPINE trial of tarextumab

Phase III study of trametinib and dabrafenib in melanoma stopped early due to benefit

FDA grants breakthrough therapy designation to pirfenidone for IPF

Cynapsus begins phase II studies of APL-130277 in Parkinson's disease

Ruthigen treats first subjects in trial of RUT-58-60

Seres Health completes enrollment in study of SER-109

Researchers develop low-cost, rapid, point-of-care test for the detection of M. tuberculosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...